**Tool Kit for Minimizing the Burden of Hidradenitis Suppurativa: Systemic Treatments for Moderate-to-Severe Disease**

|  |  |
| --- | --- |
| Resource | Address |
| Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management. *J Am Acad Dermatol*. 2019;81:91-101. | <https://pubmed.ncbi.nlm.nih.gov/30872149/> |
| Andersen PL, Nielsen RM, Sigsgaard V, Jemec GBE, Riis PT. Body image quality of life in patients with hidradenitis suppurativa compared with other dermatological disorders. *Acta Derm Venereol*. 2020;100:adv00107. | <https://pubmed.ncbi.nlm.nih.gov/32201901/> |
| Deckers IE, Kimball AB. The handicap of hidradenitis suppurativa. *Dermatol Clin*. 2016;34:17-22. | <https://pubmed.ncbi.nlm.nih.gov/26617353/> |
| Frew JW. Autoantibody-mediated macrophage responses provide the missing link between innate and adaptive immune dysfunction in hidradenitis suppurativa. *J Invest Dermatol*. 2022;142:747-749. | <https://pubmed.ncbi.nlm.nih.gov/34716008/> |
| Frew JW, Hawkes JE, Krueger JG. A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa. *F1000Res*. 2018;7:1923. | <https://pubmed.ncbi.nlm.nih.gov/31281635/> |
| Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjust population analysis of prevalence estimates for hidradenitis suppurativa in the United States. *JAMA Dermatol*. 2017;153;760-764. | <https://pubmed.ncbi.nlm.nih.gov/28492923/> |
| Garg A, Malviya N, Strunk A, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. *J Am Acad Dermatol*. 2022;86:1092-1101. | <https://pubmed.ncbi.nlm.nih.gov/33493574/> |
| Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. *J Am Acad Dermatol*. 2020;82:1045-1058. | <https://pubmed.ncbi.nlm.nih.gov/31604104/> |
| Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A comparison of international management guidelines for hidradenitis suppurativa. *Dermatology*. 2021;237:81-96. | <https://pubmed.ncbi.nlm.nih.gov/31645040/> |
| Ingram JR. The epidemiology of hidradenitis suppurativa. *Br J Dermatol*. 2020;183:990-998. | <https://pubmed.ncbi.nlm.nih.gov/32880911/> |
| Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. *Br J Dermatol*. 2019;180:1009-1017. | <https://pubmed.ncbi.nlm.nih.gov/30552762/> |
| Jørgensen AHR, Holm JG, Ghazanfar MN, Yao Y, Ring HC, Thomsen SF. Factors affecting quality of life in patients with hidradenitis suppurativa. *Arch Dermatol Res*. 2020;312:427-436. | <https://pubmed.ncbi.nlm.nih.gov/31848682/> |
| Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. *Dermatology*. 2016;232:687-691. | <https://pubmed.ncbi.nlm.nih.gov/28052274/> |
| Kurzen H, Kurokawa I, Jemec GBE, et al. What causes hidradenitis suppurativa? *Exp Dermatol*. 2008;17:455-456. | <https://pubmed.ncbi.nlm.nih.gov/18400064/> |
| Navrazhina K, Garcet S, Zheng X, Hur HB, Frew JW, Krueger JG. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression. *J Allergy Clin Immunol*. 2022;149:135-144.e12. | <https://pubmed.ncbi.nlm.nih.gov/34081946/> |
| Rondags A, van Straalen KR, van Hasselt JR, et al. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment. *Br J Dermatol*. 2019;180:1214-1220. | <https://pubmed.ncbi.nlm.nih.gov/30512186/> |
| Savage KT, Singh V, Patel ZS, et al. Pain management in hidradenitis suppurativa and a proposed treatment algorithm. *J Am Acad Dermatol*. 2021;85:187-199. | <https://pubmed.ncbi.nlm.nih.gov/32950543/> |
| Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A. Increased suicide risk in patients with hidradenitis suppurativa. *J Invest Dermatol*. 2018;138:52-57. | <https://pubmed.ncbi.nlm.nih.gov/28942360/> |
| Vekic DA, Cains GD. Hidradenitis suppurativa—management, comorbidities and monitoring. *Aust Fam Physician*. 2017;46:584-588. | <https://pubmed.ncbi.nlm.nih.gov/28787558/> |
| Wieczorek M, Walecka I. Hidradenitis suppurativa—known and unknown disease. *Reumatologia*. 2018;56:337-339. | <https://pubmed.ncbi.nlm.nih.gov/30647478/> |